A CARE (Community, Academic, Research, Education) Needs Assessment was recently conducted on current treatment protocols and views of Canadian specialists surrounding the treatment of mCRPC. This program was directed at Canadian medical oncology, radiation oncology, and urology specialists involved in identifying, referring, treating and the management of mCRPC. CARE Faculty members, Drs. Kim Chi (BCCA), Brita Danielson (University of Alberta) and Alan So (BCCA), are leading specialists in medical oncology, radiation oncology, and urology, respectively. They have endorsed this initiative and validated the ques- tionnaire content before it was distributed to their peers. The following combined analysis provides a composite of insights from each specialty on the topic of mCRPC. The commentary in this analysis is provided by Dr. Alan So, and is geared towards urologists.